Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Grifols S-A stock
Learn how to easily invest in Grifols S-A stock.
Grifols S.A is a drug manufacturers-general business based in the US. Grifols S-A shares (GRFS) are listed on the NASDAQ and all prices are listed in US Dollars. Grifols S-A employs 23,431 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Grifols S-A
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GRFS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Grifols S-A stock price (NASDAQ: GRFS)Use our graph to track the performance of GRFS stocks over time.
Grifols S-A shares at a glance
|Latest market close||$12.63|
|52-week range||$10.10 - $19.95|
|50-day moving average||$11.45|
|200-day moving average||$15.01|
|Wall St. target price||$35.23|
|Dividend yield||$0.36 (8.02%)|
|Earnings per share (TTM)||$0.55|
Buy Grifols S-A shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Grifols S-A stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Grifols S-A price performance over time
|1 week (2022-01-11)||2.68%|
|1 month (2021-12-17)||13.17%|
|3 months (2021-10-19)||-7.13%|
|6 months (2021-07-19)||-17.29%|
|1 year (2021-01-19)||-36.15%|
|2 years (2020-01-17)||-46.57%|
|3 years (2019-01-18)||19.36|
|5 years (2017-01-18)||16.68|
Is Grifols S-A stock undervalued or overvalued?
Valuing Grifols S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grifols S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Grifols S-A's P/E ratio
Grifols S-A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Grifols S-A shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Grifols S-A's PEG ratio
Grifols S-A's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2841. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Grifols S-A's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Grifols S-A's EBITDA
Grifols S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.2 billion.
The EBITDA is a measure of a Grifols S-A's overall financial performance and is widely used to measure a its profitability.
Grifols S-A financials
|Revenue TTM||$5.2 billion|
|Operating margin TTM||19.46%|
|Gross profit TTM||$2.3 billion|
|Return on assets TTM||3.98%|
|Return on equity TTM||10.73%|
|Market capitalisation||$11.4 billion|
TTM: trailing 12 months
Grifols S-A share dividends
Dividend payout ratio: 57.06% of net profits
Recently Grifols S-A has paid out, on average, around 57.06% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 8.02% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Grifols S-A shareholders could enjoy a 8.02% return on their shares, in the form of dividend payments. In Grifols S-A's case, that would currently equate to about $0.36 per share.
Grifols S-A's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Grifols S-A's most recent dividend payout was on 13 June 2021. The latest dividend was paid out to all shareholders who bought their shares by 2 June 2021 (the "ex-dividend date").
Have Grifols S-A's shares ever split?
Grifols S-A's shares were split on a 2:1 basis on 3 January 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Grifols S-A shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Grifols S-A shares which in turn could have impacted Grifols S-A's share price.
Grifols S-A share price volatility
Over the last 12 months, Grifols S-A's shares have ranged in value from as little as $10.1 up to $19.9538. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Grifols S-A's is 0.1877. This would suggest that Grifols S-A's shares are less volatile than average (for this exchange).
Grifols S-A overview
Grifols, S. A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy.
Grifols S-A in the news
Ridgewood Investments LLC Buys Vale SA, Activision Blizzard Inc, Calavo Growers Inc, Sells ...
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Frequently asked questionsWhat percentage of Grifols S-A is owned by institutions?
Currently 43.274% of Grifols S-A shares are held by institutions. How many people work for Grifols S-A?
Latest data suggests 23,431 work at Grifols S-A. When does the fiscal year end for Grifols S-A?
Grifols S-A's fiscal year ends in December. Where is Grifols S-A based?
Grifols S-A's address is: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 What is Grifols S-A's ISIN number?
Grifols S-A's international securities identification number is: US3984384087 What is Grifols S-A's CUSIP number?
Grifols S-A's Committee on Uniform Securities Identification Procedures number is: 398438200
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert